{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T22:20:18Z","timestamp":1794694818074,"version":"4.9.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T00:00:00Z","timestamp":1778371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T00:00:00Z","timestamp":1778371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41591-026-04406-6","type":"journal-article","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T11:02:10Z","timestamp":1778410930000},"page":"2647-2653","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial"],"prefix":"10.1038","volume":"32","author":[{"given":"D. J.","family":"van Veldhuisen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2581-070X","authenticated-orcid":false,"given":"M.","family":"Rienstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6906-2643","authenticated-orcid":false,"given":"A.","family":"Mosterd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Alings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5417-4415","authenticated-orcid":false,"given":"A. A.","family":"Voors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0190-2228","authenticated-orcid":false,"given":"K.","family":"Damman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. D. I.","family":"van Asselt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. L.","family":"Bouvy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6646-8070","authenticated-orcid":false,"given":"J.","family":"Schaap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. E.","family":"van der Wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1073-5337","authenticated-orcid":false,"given":"H. J. G. M.","family":"Crijns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1429-4789","authenticated-orcid":false,"given":"D. J.","family":"Touw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. A. M.","family":"Hoogslag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. E. C.","family":"van de Swaluw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J.","family":"Schuurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"van der Sluis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Bondarenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. J.","family":"R\u00f6mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Oosterhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. L.","family":"Bartels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Koudstaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. A.","family":"Dijkmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3339-1955","authenticated-orcid":false,"given":"G. C. M.","family":"Linssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Aksoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. G. R.","family":"Dorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9397-7109","authenticated-orcid":false,"given":"A.","family":"Schut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E. W.","family":"Hemels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. G.","family":"Tieleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J. A.","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. C. D.","family":"Westendorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A. T.","family":"Vijver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. H. D.","family":"Voordes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. H.","family":"de Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. L.","family":"Maas-Soer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Postmus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3798-2058","authenticated-orcid":false,"given":"G.","family":"Lunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. G. P.","family":"Tijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9705-4413","authenticated-orcid":false,"given":"P.","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,10]]},"reference":[{"key":"4406_CR1","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1161\/CIRCULATIONAHA.105.560110","volume":"113","author":"M Gheorghiade","year":"2006","unstructured":"Gheorghiade, M., van Veldhuisen, D. J. & Colucci, W. S. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation 113, 2556\u20132564 (2006).","journal-title":"Circulation"},{"key":"4406_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1056\/NEJM199702203360801","volume":"336","author":"The Digitalis Investigation Group.","year":"1997","unstructured":"The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med. 336, 525\u2013533 (1997).","journal-title":"N. Engl. J. Med."},{"key":"4406_CR3","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1093\/eurheartj\/ehad185","volume":"44","author":"DJ van Veldhuisen","year":"2023","unstructured":"van Veldhuisen, D. J. & Bauersachs, J. Digitalis in heart failure: declining use and ongoing outcome trials. Eur. Heart J. 44, 1976\u20131978 (2023).","journal-title":"Eur. Heart J."},{"key":"4406_CR4","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S0735-1097(02)01708-4","volume":"39","author":"KF Adams","year":"2002","unstructured":"Adams, K. F. et al. Clinical benefits of low serum digoxin concentrations in heart failure. J. Am. Coll. Cardiol. 39, 946\u2013953 (2002).","journal-title":"J. Am. Coll. Cardiol."},{"key":"4406_CR5","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1001\/jama.289.7.871","volume":"289","author":"SS Rathore","year":"2003","unstructured":"Rathore, S. S., Curtis, J. P., Wang, Y., Bristow, M. R. & Krumholz, H. M. Association of serum digoxin concentration and outcomes in patients with heart failure. J. Am. Med. Assoc. 289, 871 (2003).","journal-title":"J. Am. Med. Assoc."},{"key":"4406_CR6","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.ejheart.2008.08.005","volume":"10","author":"K Dickstein","year":"2008","unstructured":"Dickstein, K. et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008\u2021. Eur. J. Heart Fail. 10, 933\u2013989 (2008).","journal-title":"Eur. J. Heart Fail."},{"key":"4406_CR7","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1001\/jama.2020.23138","volume":"324","author":"D Kotecha","year":"2020","unstructured":"Kotecha, D. et al. Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life. J. Am. Med. Assoc. 324, 2497 (2020).","journal-title":"J. Am. Med. Assoc."},{"key":"4406_CR8","doi-asserted-by":"publisher","unstructured":"Bunting, K. V. et al. Low-dose digoxin improves cardiac function in patients with heart failure, preserved ejection fraction and atrial fibrillation\u2014the RATE-AF randomized trial. Eur. J. Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.70022 (2025).","DOI":"10.1002\/ejhf.70022"},{"key":"4406_CR9","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1056\/NEJMoa2415471","volume":"393","author":"U Bavendiek","year":"2025","unstructured":"Bavendiek, U. et al. Digitoxin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 393, 1155\u20131165 (2025).","journal-title":"N. Engl. J. Med."},{"key":"4406_CR10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0140-6736(25)01851-3","volume":"407","author":"A Cannata","year":"2026","unstructured":"Cannata, A., Crespo-Leiro, M. G., Bromage, D. I., Ruschitzka, F. & McDonagh, T. A. Heart failure with reduced ejection fraction. Lancet 407, 529\u2013542 (2026).","journal-title":"Lancet"},{"key":"4406_CR11","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1002\/ejhf.3428","volume":"26","author":"DJ van Veldhuisen","year":"2024","unstructured":"van Veldhuisen, D. J. et al. Efficacy and safety of low-dose digoxin in patients with heart failure. Rationale and design of the DECISION trial. Eur. J. Heart Fail. 26, 2223\u20132230 (2024).","journal-title":"Eur. J. Heart Fail."},{"key":"4406_CR12","doi-asserted-by":"publisher","unstructured":"van der Meer, P. et al. Heart failure patients with reduced or mildly reduced ejection fraction: baseline characteristics of the low-dose digoxin outcome DECISION trial. Eur. J. Heart Fail. https:\/\/doi.org\/10.1093\/ejhf\/xuag073 (2026).","DOI":"10.1093\/ejhf\/xuag073"},{"key":"4406_CR13","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1093\/eurheartj\/ehaa461","volume":"41","author":"SD Anker","year":"2020","unstructured":"Anker, S. D. et al. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur. Heart J. 41, 2109\u20132117 (2020).","journal-title":"Eur. Heart J."},{"key":"4406_CR14","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1056\/NEJMoa021266","volume":"347","author":"SS Rathore","year":"2002","unstructured":"Rathore, S. S., Wang, Y. & Krumholz, H. M. Sex-based differences in the effect of digoxin for the treatment of heart failure. N. Engl. J. Med. 347, 1403\u20131411 (2002).","journal-title":"N. Engl. J. Med."},{"key":"4406_CR15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.jacc.2005.02.091","volume":"46","author":"KF Adams","year":"2005","unstructured":"Adams, K. F. et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the Digitalis Investigation Group Trial. J. Am. Coll. Cardiol. 46, 497\u2013504 (2005).","journal-title":"J. Am. Coll. Cardiol."},{"key":"4406_CR16","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1093\/eurheartj\/ehs004","volume":"33","author":"D Castagno","year":"2012","unstructured":"Castagno, D., Petrie, M. C., Claggett, B. & McMurray, J. Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. Eur. Heart J. 33, 1137\u20131141 (2012).","journal-title":"Eur. Heart J."},{"key":"4406_CR17","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1002\/ejhf.1160","volume":"20","author":"AH Abdul-Rahim","year":"2018","unstructured":"Abdul-Rahim, A. H. et al. Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction. Eur. J. Heart Fail. 20, 1139\u20131145 (2018).","journal-title":"Eur. J. Heart Fail."},{"key":"4406_CR18","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ijcard.2018.12.069","volume":"280","author":"S Kasahara","year":"2019","unstructured":"Kasahara, S. et al. Conversion formula from B-type natriuretic peptide to N-terminal proBNP values in patients with cardiovascular diseases. Int. J. Cardiol. 280, 184\u2013189 (2019).","journal-title":"Int. J. Cardiol."},{"key":"4406_CR19","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski, P. et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. J. Heart Fail. 18, 891\u2013975 (2016).","journal-title":"Eur. J. Heart Fail."},{"key":"4406_CR20","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof, P. et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J. 37, 2893\u20132962 (2016).","journal-title":"Eur. Heart J."},{"key":"4406_CR21","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/1467-9868.00259","volume":"62","author":"DY Lin","year":"2000","unstructured":"Lin, D. Y., Wei, L. J., Yang, I. & Ying, Z. Semiparametric regression for the mean and rate functions of recurrent events. J. R. Stat. Soc. B 62, 711\u2013730 (2000).","journal-title":"J. R. Stat. Soc. B"},{"key":"4406_CR22","unstructured":"Bos, J. C., De Boer, R. & Franz, E. Staat van infectieziekten in Nederland, 2023. Dutch National Institute for Public Health and the Environment https:\/\/rivm.openrepository.com\/entities\/publication\/e571415a-ac27-43b8-a6ab-d6886d021013 (2024)."},{"key":"4406_CR23","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","volume":"396","author":"P Ponikowski","year":"2020","unstructured":"Ponikowski, P. et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 396, 1895\u20131904 (2020).","journal-title":"Lancet"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04406-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04406-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04406-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:02:09Z","timestamp":1784210529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04406-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,10]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4406"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04406-6","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,10]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.J.v.V. is an established investigator of the Netherlands Heart Foundation, but has no conflicts of interest to report (and has received no personal payments in relation to the DECISION Trial). M.R. has received an unrestricted research grant from the Netherlands Heart Foundation, which is conducted in collaboration with and supported by the Dutch CardioVascular Alliance, 01-002-2022-0118 EmbRACE. He has also received unrestricted research grants from the Netherlands Cardiovascular Research Initiative: an initiative with support of the Netherlands Heart Foundation; RACE V (CVON 2014\u20139) and RED-CVD (CVON2017-11). He has also received an unrestricted research grant from the European Union\u2019s Horizon 2020 research and innovation program under grant agreement EHRA-PATHS (945260). In addition, he has received consultancy fees from Bayer, InCarda Therapeutics and Novartis to the institution and speaker fees from Daiichi Sankyo and Pfizer, which all have been paid to his employer UMC Groningen. A.M. is the Chair of the Scientific Advisory Board and Chair of the Clinical Trial Committee of the Netherlands Heart Foundation, for which he receives no payments. He has no other conflicts of interest. M.A. reports no conflicts of interest. A.A.V. has received consultancy fees and\/or research support from Anacardio, Astra Zeneca, Bayer AG, Boehringer Ingelheim, Cardurion, Corteria, EliLilly, Merck, Novartis, Novo Nordisk, QTsense, Rycarma and SalubrisBio, which all have been paid to his employer, UMC Groningen. K.D. reports speaker\/consultancy fees from Abbott, Astra zeneca, Boehringer Ingelheim, Novartis, FIRE1 and Echosense, which all have been paid to his employer UMC Groningen. A.D.I.v.A. reports no conflict of interest. M.L.B. reports no conflicts of interest. J.S. has received payments for lectures and advisory boards from General Electric, Boehringer, Novo Nordisk, Novartis, Lilly, Astra Zeneca and Pharma Nord, not related to the submitted work. E.E.v.d.W. reports no conflicts of interest. H.J.G.M.C. has received fees and honoraria for lectures, education and scientific advice activities from Atricure, Medtronic and Armgo. D.J.T. reports no conflicts of interest. P.A.M.H. reports no conflicts of interest. J.E.C.V.d.S. has held paid lectures for Abbott; there are no other conflicts of interest. R.J.S. reports no conflicts of interest. A.v.d.S. reports no conflicts of interest. O.B. reports no conflicts of interest. T.J.R. reports no conflicts of interest. T.O. reports no conflicts of interest. G.L.B. reports no conflicts of interest. S.K. has received consultancy fees or educational grants from Astra Zeneca, Novo Nordisk, Boehringer Ingelheim, Novartis, CSL, Amarin, Bayer and Amgen. P.A.D. reports no conflicts of interest. G.C.M.L. reports no conflicts of interest. I.A. reports no conflicts of interest. H.G.R.D. reports no conflicts of interest. A.S. reports no conflicts of interest. M.E.W.H. reports no conflicts of interest. R.G.T. reports grants from Medtronic and Abbott, and personal fees from Boehringer Ingelheim, Daiichi Sankyo, Bayer and Pfizer\/Bristol Meyer Squibb all outside the submitted work. D.J.A.L. reports no conflicts of interest. I.C.D.W. reports no conflicts of interest. M.A.T.V. reports no conflicts of interest. G.H.D.V. reports no conflicts of interest. A.H.d.V. has no conflicts of interest. E.L.M.-S. reports no conflicts of interest. D.P. reports no conflicts of interest. G.L. reports no conflicts of interest. J.G.P.T. reports no conflicts of interest. P.v.d.M. is supported by a grant from the European Research Council (ERC CoG 101045236, DISSECT-HF). He has received consultancy fees and\/or grants from Novartis, Pharmacosmos, Vifor Pharma, Astra Zeneca, Pfizer, Pharma Nord, BridgeBio, Novo Nordisk, Bayer, Boehringer Ingelheim and Ionis, which all have been paid to his employer, UMC Groningen.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}